Association of thyroid peroxidase antibody with the RNF213 p.R4810K variant in ischemic stroke/transient ischemic attack
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved..
BACKGROUND AND AIMS: RNF213 is a susceptibility gene for moyamoya disease and vasospastic angina, with a second hit considered necessary for their development. Elevated thyroid peroxidase antibody (TPO-Ab) levels have been observed in both diseases, suggesting a possible role of TPO-Ab as a second hit for developing RNF213-related vasculopathy. We investigated the association of TPO-Ab levels with RNF213-related ischemic stroke (IS)/transient ischemic attack (TIA), other than moyamoya disease.
METHODS: From the National Cerebral and Cardiovascular Center Genome Registry, a multicenter, prospective, observational study, we enrolled patients with IS/TIA who were admitted within 1 week of onset. Patients with IS/TIA due to definite moyamoya disease or hemorrhagic stroke were excluded. Participants underwent genotyping for RNF213 p. R4810K, and baseline characteristics and TPO-Ab levels were compared between RNF213 p. R4810K variant carriers and non-carriers.
RESULTS: In total, 2090 IS/TIA patients were analyzed [733 women (35.1%); median age 74 (interquartile range, 63-81) years, baseline NIHSS score 3 (2-6)], and 85 (4.1%) of them carried the variant. Median TPO-Ab levels were significantly higher in variant carriers (8.5 IU/mL vs. 2.1 IU/mL, p < 0.01), who also showed a higher frequency of elevated TPO-Ab levels (>16 IU/mL) (27.1% vs. 4.4%). In the multivariate analysis, presence of the RNF213 p. R4810K variant (adjusted odds ratio, 12.42; 95% confidential interval, 6.23-24.75) was significantly associated with elevated TPO-Ab levels.
CONCLUSIONS: Elevated TPO-Ab levels may be significantly associated with presence of the RNF213 p. R4810K variant in IS/TIA patients. Thus, TPO-Ab may inherently modify IS/TIA development in RNF213 p. R4810K variant carriers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:382 |
|---|---|
| Enthalten in: |
Atherosclerosis - 382(2023) vom: 01. Okt., Seite 117281 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoshimoto, Takeshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ischemic stroke |
|---|
| Anmerkungen: |
Date Revised 12.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.atherosclerosis.2023.117281 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362191549 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362191549 | ||
| 003 | DE-627 | ||
| 005 | 20231226090728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.atherosclerosis.2023.117281 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362191549 | ||
| 035 | |a (NLM)37722316 | ||
| 035 | |a (PII)S0021-9150(23)05202-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoshimoto, Takeshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of thyroid peroxidase antibody with the RNF213 p.R4810K variant in ischemic stroke/transient ischemic attack |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: RNF213 is a susceptibility gene for moyamoya disease and vasospastic angina, with a second hit considered necessary for their development. Elevated thyroid peroxidase antibody (TPO-Ab) levels have been observed in both diseases, suggesting a possible role of TPO-Ab as a second hit for developing RNF213-related vasculopathy. We investigated the association of TPO-Ab levels with RNF213-related ischemic stroke (IS)/transient ischemic attack (TIA), other than moyamoya disease | ||
| 520 | |a METHODS: From the National Cerebral and Cardiovascular Center Genome Registry, a multicenter, prospective, observational study, we enrolled patients with IS/TIA who were admitted within 1 week of onset. Patients with IS/TIA due to definite moyamoya disease or hemorrhagic stroke were excluded. Participants underwent genotyping for RNF213 p. R4810K, and baseline characteristics and TPO-Ab levels were compared between RNF213 p. R4810K variant carriers and non-carriers | ||
| 520 | |a RESULTS: In total, 2090 IS/TIA patients were analyzed [733 women (35.1%); median age 74 (interquartile range, 63-81) years, baseline NIHSS score 3 (2-6)], and 85 (4.1%) of them carried the variant. Median TPO-Ab levels were significantly higher in variant carriers (8.5 IU/mL vs. 2.1 IU/mL, p < 0.01), who also showed a higher frequency of elevated TPO-Ab levels (>16 IU/mL) (27.1% vs. 4.4%). In the multivariate analysis, presence of the RNF213 p. R4810K variant (adjusted odds ratio, 12.42; 95% confidential interval, 6.23-24.75) was significantly associated with elevated TPO-Ab levels | ||
| 520 | |a CONCLUSIONS: Elevated TPO-Ab levels may be significantly associated with presence of the RNF213 p. R4810K variant in IS/TIA patients. Thus, TPO-Ab may inherently modify IS/TIA development in RNF213 p. R4810K variant carriers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ischemic stroke | |
| 650 | 4 | |a RNF213 variant | |
| 650 | 4 | |a TPO-Ab | |
| 650 | 4 | |a Transient ischemic attack | |
| 700 | 1 | |a Ishiyama, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Hattori, Yorito |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Kunihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Yoko |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohyagi, Yasumasa |e verfasserin |4 aut | |
| 700 | 1 | |a Akaiwa, Yasuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Miyamoto, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kawamoto, Michi |e verfasserin |4 aut | |
| 700 | 1 | |a Ichijo, Masahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Hiroyasu |e verfasserin |4 aut | |
| 700 | 1 | |a Matsukawa, Noriyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Mizuno, Toshiki |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuyama, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Tomimoto, Hidekazu |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakami, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Toyoda, Kazunori |e verfasserin |4 aut | |
| 700 | 1 | |a Koga, Masatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ihara, Masafumi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Atherosclerosis |d 1970 |g 382(2023) vom: 01. Okt., Seite 117281 |w (DE-627)NLM000087394 |x 1879-1484 |7 nnns |
| 773 | 1 | 8 | |g volume:382 |g year:2023 |g day:01 |g month:10 |g pages:117281 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.atherosclerosis.2023.117281 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 382 |j 2023 |b 01 |c 10 |h 117281 | ||